479 related articles for article (PubMed ID: 33059715)
41. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A
Emson C; Corren J; Sałapa K; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():91-99. PubMed ID: 33568920
[TBL] [Abstract][Full Text] [Related]
42. Severe Asthmatic Responses: The Impact of TSLP.
Theofani E; Tsitsopoulou A; Morianos I; Semitekolou M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108740
[TBL] [Abstract][Full Text] [Related]
43. Tezepelumab: First Approval.
Hoy SM
Drugs; 2022 Mar; 82(4):461-468. PubMed ID: 35184265
[TBL] [Abstract][Full Text] [Related]
44. Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma.
Sverrild A; Cerps S; Nieto-Fontarigo JJ; Ramu S; Hvidtfeldt M; Menzel M; Kearley J; Griffiths JM; Parnes JR; Porsbjerg C; Uller L
Allergy; 2024 Mar; 79(3):656-666. PubMed ID: 37846599
[TBL] [Abstract][Full Text] [Related]
45. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P; Manzetti GM; Bettin FR; D'Auria M; Calzetta L
Expert Opin Investig Drugs; 2024 Jan; 33(1):39-49. PubMed ID: 38206116
[TBL] [Abstract][Full Text] [Related]
46. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
[TBL] [Abstract][Full Text] [Related]
47. TSLP Inhibitors for Asthma: Current Status and Future Prospects.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Drugs; 2020 Apr; 80(5):449-458. PubMed ID: 32078149
[TBL] [Abstract][Full Text] [Related]
48. A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
Sakamoto K; Matsuki S; Irie S; Uchida N; Hayashi N; Horiuchi M; Ren S
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):833-840. PubMed ID: 31960624
[TBL] [Abstract][Full Text] [Related]
49. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
Menzies-Gow A; Bourdin A; Chupp G; Israel E; Hellqvist Å; Hunter G; Roseti SL; Ambrose CS; Llanos JP; Cook B; Corren J; Colice G
Ann Allergy Asthma Immunol; 2023 Sep; 131(3):343-348.e2. PubMed ID: 37263380
[TBL] [Abstract][Full Text] [Related]
50. [Tezepelumab: a new option for the treatment of severe asthma].
Maldonado-Ríos VA; Ardila-Herrera JC; Galicia-Sánchez LM; Celis-Preciado CA
Rev Med Inst Mex Seguro Soc; 2023 Nov; 61(6):841-848. PubMed ID: 37995367
[TBL] [Abstract][Full Text] [Related]
51. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
Can Respir J; 2019; 2019():8607657. PubMed ID: 31885750
[TBL] [Abstract][Full Text] [Related]
52. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.
Laidlaw TM; Menzies-Gow A; Caveney S; Han JK; Martin N; Israel E; Lee JK; Llanos JP; Martin N; Megally A; Parikh B; Vong S; Welte T; Corren J
J Asthma Allergy; 2023; 16():915-932. PubMed ID: 37692126
[TBL] [Abstract][Full Text] [Related]
53. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.
Duchesne M; Okoye I; Lacy P
Front Immunol; 2022; 13():975914. PubMed ID: 36311787
[TBL] [Abstract][Full Text] [Related]
54. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
55. Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Corren J; Menzies-Gow A; Bimmel J; McGuinness A; Almqvist G; Bowen K; Griffiths JM; Ponnarambil S; Bourdin A; Israel E; Colice G; Brightling CE; Wechsler ME;
Immunotherapy; 2023 Nov; 15(16):1327-1340. PubMed ID: 37772607
[TBL] [Abstract][Full Text] [Related]
56. Real-world data on tezepelumab in patients with severe asthma in Germany.
Biener L; Mümmler C; Hinze CA; Suhling H; Korn S; Fisser C; Biener A; Pizarro C; Lenoir A; Hackl C; Skowasch D; Milger K
J Allergy Clin Immunol Pract; 2024 Jun; ():. PubMed ID: 38866104
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
Carr TF; Moore WC; Kraft M; Brusselle G; Castro M; Chupp GL; Wechsler ME; Hunter G; Lindsley AW; Llanos JP; Burke LK; Chandarana S; Ambrose CS
Adv Ther; 2024 May; ():. PubMed ID: 38802635
[TBL] [Abstract][Full Text] [Related]
58. Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
Ragnoli B; Morjaria J; Pignatti P; Montuschi P; Barbieri M; Mondini L; Ruggero L; Trotta L; Malerba M
Ther Adv Chronic Dis; 2022; 13():20406223221097327. PubMed ID: 35655942
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials.
Lin F; Yu B; Deng B; He R
Medicine (Baltimore); 2023 Aug; 102(32):e34746. PubMed ID: 37565847
[TBL] [Abstract][Full Text] [Related]
60. Successful Treatment of Eosinophilic Chronic Rhinosinusitis and Secretory Otitis Media in Refractory Asthma With Thymic Stromal Lymphopoietin (TSLP) Receptor Monoclonal Antibody.
Kawashima K; Matsuno O; Okuno M; Kawabe T; Hanada Y
Cureus; 2023 Oct; 15(10):e47798. PubMed ID: 38022039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
